Dr. Martens (LON:DOCS - Get Free Report)'s stock had its "hold" rating reiterated by equities research analysts at Deutsche Bank Aktiengesellschaft in a report issued on Friday,London Stock Exchange reports.
Separately, Royal Bank Of Canada lowered their target price on Dr. Martens from GBX 7,000 ($94.43) to GBX 6,000 ($80.94) and set a "sector perform" rating on the stock in a report on Monday, May 19th.
Read Our Latest Report on DOCS
Dr. Martens Stock Performance
LON DOCS traded up GBX 0.30 ($0.00) on Friday, reaching GBX 79 ($1.07). The stock had a trading volume of 750,626 shares, compared to its average volume of 2,157,448. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. Dr. Martens has a 12-month low of GBX 43.02 ($0.58) and a 12-month high of GBX 83.30 ($1.12). The business's 50-day moving average price is GBX 67.55 and its 200 day moving average price is GBX 64.01. The stock has a market cap of £766.90 million, a P/E ratio of 11.20, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11.
Dr. Martens (LON:DOCS - Get Free Report) last released its earnings results on Thursday, June 5th. The company reported GBX 2.40 ($0.03) earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. As a group, equities analysts expect that Dr. Martens will post 2.5809394 earnings per share for the current year.
Dr. Martens Company Profile
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Further Reading
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
